KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Operating Leases (2019 - 2025)

Historic Operating Leases for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2025 value amounting to $767000.0.

  • Esperion Therapeutics' Operating Leases fell 7675.05% to $767000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $767000.0, marking a year-over-year decrease of 7675.05%. This contributed to the annual value of $2.6 million for FY2024, which is 1490.07% down from last year.
  • According to the latest figures from Q3 2025, Esperion Therapeutics' Operating Leases is $767000.0, which was down 7675.05% from $1.3 million recorded in Q2 2025.
  • Over the past 5 years, Esperion Therapeutics' Operating Leases peaked at $4.4 million during Q1 2024, and registered a low of $47000.0 during Q3 2022.
  • Its 5-year average for Operating Leases is $1.8 million, with a median of $1.7 million in 2023.
  • Its Operating Leases has fluctuated over the past 5 years, first crashed by 9642.04% in 2022, then surged by 425957.45% in 2023.
  • Over the past 5 years, Esperion Therapeutics' Operating Leases (Quarter) stood at $524000.0 in 2021, then grew by 26.91% to $665000.0 in 2022, then surged by 354.14% to $3.0 million in 2023, then decreased by 14.9% to $2.6 million in 2024, then crashed by 70.16% to $767000.0 in 2025.
  • Its Operating Leases was $767000.0 in Q3 2025, compared to $1.3 million in Q2 2025 and $2.0 million in Q1 2025.